UNASSIGNED: @entity2971 ( @entity2971 ) are the most frequent @entity5 in male @entity1 between 15 and 45 years of age. @entity900 -based chemotherapy shows excellent cure rates, but @entity1 with @entity900 -resistant @entity2971 have a poor prognosis. @entity9815 ( @entity9815 , Vargatef) inhibits the receptor classes vascular endothelial growth factor receptor, platelet derived growth factor receptor, and fibroblast growth factor receptor, and has shown activity against @entity5 , as well as in @entity82 and @entity1732 -induced @entity651 . Here, we investigated the antineoplastic and antiangiogenic properties of @entity9815 in @entity900 -resistant and @entity900 -sensitive @entity1777 cells, both alone and in combination with classical cytotoxic agents such as @entity900 , @entity2879 , and @entity1732 . The half-maximal inhibitory concentration (IC50) of @entity9815 was 4.5  0.43    mol/l, 3.1  0.45    mol/l, and 3.6  0.33    mol/l in @entity900 -sensitive NTERA2, 2102Ep, and @entity1 cells, whereas the IC50 doses of the @entity900 -resistant counterparts were 6.6  0.37    mol/l (NTERA2-R), 4.5  0.83    mol/l (2102Ep-R), and 6.1  0.41    mol/l (NCCIT-R), respectively. Single treatment with @entity9815 induced apoptosis and resulted in a sustained reduction in the capacity of colony formation in both @entity900 -sensitive and @entity900 -resistant @entity1777 cells. Cell cycle analysis showed that @entity9815 induced a strong G0/G1-phase arrest in all investigated cell lines. Combination treatment with @entity900 did not result in additive, synergistic, or antagonistic effects. The in-vivo activity was studied using the chorioallantoic membrane assay and indicated the antiangiogenic potency of @entity9815 with markedly reduced microvessel density. Topical treatment of inoculated @entity5 plaques resulted in a significant reduction of the @entity5 size. This indicates that @entity9815 might be a promising substance in the treatment of @entity1777 .

Activity of @entity9815 in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'NCCIT'] @entity9815 :: ('MESH:C530716', 'Chemical') :: ['BIBF 1120', 'nintedanib', 'Nintedanib'] @entity82 :: ('MESH:D005355', 'Disease') :: ['idiopathic lung fibrosis'] @entity2971 :: ('MESH:D009373', 'Disease') :: ['GCTs', 'Germ cell tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'many tumors', 'malignancy'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity1777 :: ('MESH:C537296', 'Disease') :: ['GCT'] @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']
@entity2971 :: (MESH:D009373,Disease) :: ['germ cell tumors']
